Gemma Biotherapeutics ("GEMMABio"), a clinical‑stage, global, genetic medicines company, today announced the presentation of preclinical data supporting candidate declaration for GB703, a novel, ...
Regenxbio’s gene therapy for Duchenne muscular dystrophy has smashed the primary endpoint of its pivotal trial, securing a ...
The Muscular Dystrophy Association (MDA) today announced a $100,000 investment by BridgeBio to strengthen multidisciplinary care for people living with limb-girdle muscular dystrophy (LGMD). Through ...
Regenxbio said top-line results showed it met its primary endpoint in a Phase 3 study of its RGX-202 gene therapy for Duchenne Muscular Dystrophy. The trial met its primary endpoint with high ...
CNW/ - Families, friends, and supporters from coast to coast to coast are walking, running, and rolling this May, in support ...
Carnahan's doing it to raise money for muscular dystrophy. There are 40 different neuromuscular disorders and we're just trying to raise money and awareness for that to help people along their way if ...
The muscular dystrophies represent disorders of progressive muscular degeneration and weakness. As a group, they exhibit clinical heterogeneity that reflects diverse molecular mechanisms responsible ...
For Duchenne and Becker muscular dystrophies, muscle biopsy may show whether dystrophin, a muscle protein, is missing or abnormal, and DNA testing is used to analyze the condition of the related gene.
Dutch Bros’ annual “Drink One for Dane” fundraiser returns Friday, May 15, with the coffee chain bringing back its ...
2d
Regenxbio Meets Primary Endpoint in Duchenne Muscular Dystrophy Study, Swings to 1Q Loss -- Update
Regenxbio met its primary endpoint in a Phase 3 study of its Duchenne muscular dystrophy treatment, but it swung to a first-quarter loss as revenue plunged. Shares fell 20% to $8.06 in premarket ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results